Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSOFree Report) in a report released on Saturday morning. The brokerage issued a hold rating on the stock.

A number of other analysts have also weighed in on EKSO. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, January 14th. Lake Street Capital lowered their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Read Our Latest Research Report on EKSO

Ekso Bionics Stock Performance

NASDAQ EKSO opened at $0.57 on Friday. The firm has a market cap of $12.55 million, a price-to-earnings ratio of -0.88 and a beta of 1.46. The company has a 50 day moving average of $0.63 and a 200-day moving average of $0.85. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. Ekso Bionics has a 1-year low of $0.47 and a 1-year high of $2.16.

Ekso Bionics Company Profile

(Get Free Report)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Featured Stories

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.